Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endotoxin as a drug target.

Steven M Opal1, Thomas Glück

  • 1Infectious Disease Division, Brown Medical School, Providence, RI, USA.

Critical Care Medicine
|January 25, 2003
PubMed
Summary

Antiendotoxin therapies show promise in preclinical models for preventing and treating septic shock. However, clinical trials have not yet proven their effectiveness in reducing mortality rates in human patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A circuitous route to the diagnosis of a very rare disease].

Innere Medizin (Heidelberg, Germany)·2025
Same author

Role and benefits of infectious diseases specialists in the COVID-19 pandemic: Multilevel analysis of care provision in German hospitals using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS) cohort.

Infection·2024
Same author

Humoral immunity in dually vaccinated SARS-CoV-2-naïve individuals and in booster-vaccinated COVID-19-convalescent subjects.

Infection·2022
Same author

Omicron's binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals.

iScience·2022
Same author

Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel.

Infection·2021
Same author

Evaluation of a Broad Panel of SARS-CoV-2 Serological Tests for Diagnostic Use.

Journal of clinical medicine·2021

Area of Science:

  • Immunology and Infectious Diseases
  • Critical Care Medicine
  • Pharmacology

Background:

  • Bacterial endotoxin is a key mediator of severe sepsis and septic shock, triggering intense inflammatory and procoagulant responses.
  • Endotoxemia is frequently detected in human septic shock patients, regardless of the specific infecting microorganism.

Purpose of the Study:

  • To critically review preclinical and clinical evidence on the efficacy of antiendotoxin therapeutic strategies.
  • To evaluate the potential of targeting endotoxin for the prevention and treatment of severe sepsis and septic shock.

Main Methods:

  • A comprehensive literature review spanning 30 years of basic and clinical research.
  • Analysis of studies investigating endotoxin inhibition in experimental sepsis models and human clinical trials.

Main Results:

  • Preclinical studies consistently demonstrate survival benefits from endotoxin inhibition in experimental sepsis.
  • Clinical trials of antiendotoxin strategies have not yet yielded reproducible survival benefits in septic patients.
  • Endotoxin is present in systemic circulation in most human septic shock cases.

Conclusions:

  • Despite strong preclinical evidence, the clinical utility of antiendotoxin approaches for reducing septic shock mortality remains unproven.
  • Ongoing clinical trials with specific endotoxin inhibitors are crucial to determine their therapeutic value in managing septic shock.

Related Experiment Videos